Paperpal Prime Logo

Journal for ImmunoTherapy of Cancer : Impact Factor & More

eISSN: 2051-1426pISSN: 2051-1426
JournalOpen Access

Key Metrics

CiteScore
14.3
Eigenfactor
0.01 - 0.05
Impact Factor
10 - 15
Scite Index
0.90 5-Year SI
SJR
Q1Oncology
SNIP
2.23
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMJ PUBLISHING GROUP
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2885
Publication Time18
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorSociety for Immunotherapy of Cancer
FrequencyContinuous publication
Publication Start Year2013
Publisher URLVisit website
Website URLVisit website
Publication Details
Other chargesVisit website
PlagiarismVisit website
Publication Time 18
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC, CC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Journal for ImmunoTherapy of Cancer ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Journal for ImmunoTherapy of Cancer

Clinical trial landscape and translational prospects of natural killer cell-based immunotherapy: an analysis based on the INFORMA database.
  • 7 Aug 2026
  • Journal for immunotherapy of cancer
Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy.
  • 7 Aug 2026
  • Journal for immunotherapy of cancer
Streptococcus anginosus-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer
  • 6 Aug 2026
  • Journal for Immunotherapy of Cancer
TGF-\u03b21 drives neutrophil extracellular traps formation to promote CD8+ T cell exhaustion via the ERK-c-Fos-JunB axis, mediating gastric cancer immunotherapy resistance
  • 4 Aug 2026
  • Journal for Immunotherapy of Cancer
\u03b2-glucan elicits APOE-dependent peripheral trained immunity to suppress hepatocellular carcinoma
  • 4 Aug 2026
  • Journal for Immunotherapy of Cancer
\u201cYong\u201d syndrome\u2013cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer
  • 4 Aug 2026
  • Journal for Immunotherapy of Cancer
Clinical trial landscape and translational prospects of natural killer cell-based immunotherapy: an analysis based on the INFORMA database.
  • 7 Aug 2026
  • Journal for immunotherapy of cancer
Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy.
  • 7 Aug 2026
  • Journal for immunotherapy of cancer
Streptococcus anginosus-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer
  • 6 Aug 2026
  • Journal for Immunotherapy of Cancer
TGF-\u03b21 drives neutrophil extracellular traps formation to promote CD8+ T cell exhaustion via the ERK-c-Fos-JunB axis, mediating gastric cancer immunotherapy resistance
  • 4 Aug 2026
  • Journal for Immunotherapy of Cancer
\u03b2-glucan elicits APOE-dependent peripheral trained immunity to suppress hepatocellular carcinoma
  • 4 Aug 2026
  • Journal for Immunotherapy of Cancer
\u201cYong\u201d syndrome\u2013cGAS-STING axis: a TCM syndrome-based hypothesis for overcoming primary anti-PD-1 resistance in gastric cancer
  • 4 Aug 2026
  • Journal for Immunotherapy of Cancer

FAQs on Journal for ImmunoTherapy of Cancer